EY German Biotechnology Report 2021

German Biotechnology Industry reached record financing in 2020

As every year in April, EY published its latest German Biotechnology Report. In a press release (only available in German language) dated April 20, 2021, the auditing and consulting company provided information on the following key statements:

• Capital raised reached 3.1 billion euros - an increase of 146 percent compared to record year 2018
• Two IPOs by CureVac and Immatics in the U.S.
• Sales, number of employees and research and development spending rise significantly at listed biotechs
• Venture capital in Germany increases significantly - United Kingdom European frontrunner
• Number of alliances declines, but volume increases by 57 percent to 6.9 billion euros

Download the study (only available in German language) here.

Here you can find out more about the "history" of the report. Please contact me if you have any questions about statements made in this study or about previous or future developments.